Acceptability of the nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction

Contraception

Volumn 90, Issue 5, 2014, Pages 514-521

  Merkatz, Ruth B ^a   Plagianos, Marlena ^a   Hoskin, Elena ^a   Cooney, Michael ^a   Hewett, Paul C ^b   Mensch, Barbara S ^a  

^a POPULATION COUNCIL   (United States)

^b POPULATION COUNCIL   (Zambia)

Author keywords

Acceptability model; Hormonal contraception; Long acting delivery system; Method introduction; Vaginal ring

Indexed keywords

ELCOMETRINE; CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; CONTRACEPTION; FEMALE; FISHER EXACT TEST; HUMAN; LIKERT SCALE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; SATISFACTION; SEXUAL BEHAVIOR; VAGINA RING; ADOLESCENT; FACTORIAL ANALYSIS; FEMALE CONTRACEPTIVE DEVICE; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; ETHINYL ESTRADIOL; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MODELS, THEORETICAL; NORPROGESTERONES; PATIENT ACCEPTANCE OF HEALTH CARE; YOUNG ADULT;

EID: 84923209323     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2014.05.015     Document Type: Article

References (30)

1. Sivin I, Mishell DR, Alvarez F, Brache B, Elomaa D, Lahteenmaki P, et al. Contraceptive vaginal rings releasing Nestorone and ethinyl estradiol: a 1-year dose-finding trial. Contraception 2005;71:122-9.
2. Brache V, Payán LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception 2013;87(3):264-72.
3. Faundes A, Hardy EE, Reyes Q, Pastene L, Portes-Carrasco R. Acceptability of the contraceptive vaginal ring by rural and urban populations in two Latin American countries. Contraception 1981;24:393-414.
4. Darroch J, Sedgh G, Ball H. Contraceptives technologies: responding to women's needs. NewYork: Guttmacher Institute; 2011.
5. Barot S. In search of breakthroughs: renewing support for contraceptive research and development. Guttmacher Policy Review Winter, 16 (1). 2013.
6. Peterson HB, Darmstadt GL, Bongaarts J. Meeting the unmet need for family planning; now is the time. Lancet 2013;381(9879):1696-9.
7. Hardy EE, Reyes Q, Gómez F, Portes-Carrasco R, Faúndes A. User's perception of the contraceptive vaginal ring: a field study in Brazil and the Dominican Republic. Stud Fam Plan 1983;14:284-90.
8. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003;67(3):187-94.
9. Strauss J, Nass SJ. New frontiers in contraceptive research: a blueprint for action. Institute of Medicine, National Academy of Sciences; 200410.
10. RamaRao S, Clark H, Merkatz R, Sussman H, Sitruk-Ware R. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception 2013;88:591-8.
11. Sanchez S, Araya C, Tijero M, Diaz S. Women's perceptions and experience with the progesterone vaginal ring for contraception during breastfeeding. Reprod Health Matters 1997:49-57.
12. Schafer JE, Osborne LM, Davis AR. Westhoff C acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006;73(5):488-92.
13. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008;111:267-77.
14. Kerns J, Darney P. Vaginal ring contraception. Contraception 2011;83(2):107-15.
15. Weisberg E, Fraser IS, Mishell DR, Lacarra M, Bardin CW. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception 1995;51:39-44.
16. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16(3):463-75.
17. Ahrendt HJ, Nisand I, Bastianelli C, Gomez MA, Gemzell-Danielsson K, Urdl W, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 micrograms of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451-7.
18. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004;104:555-63.
19. Madden T, Blumenthal P. Contraceptive vaginal ring. Clin Obstet Gynecol 2007;50(4):878-85.
20. Shimoni N, Westhoff C. Review of the vaginal contraceptive ring (NuvaRing). J Fam Plann Reprod Health Care 2008;34(4):247-50.
21. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006;74:220-3.
22. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008;13(1):31-8.
23. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100(3):585-93.
24. Daniels K, Mosher WD, Jones J. Contraceptive methods women have ever used: United States, 1982-2010. National Health Statistics Report; 2013. [62].
25. Hewett PC, Mensch BS, Erulkar A. Consistency in the reporting of sexual behavior by adolescent girls in Kenya: a comparison of interviewing methods. Sex Transm Infect 2004;80(Suppl 2):ii43-8.
26. Nunnally JC. Psychometric theory. USA: McGraw Hill, Inc.; 1978.
27. Hosmer David W, Lemeshow Stanley. Applied logistic regression. New York: Wiley; 2000.
28. Montgomery ET, van der Straten A, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav 2012;16(7):1787-98.
29. Ballagh SA. Vaginal rings for menopausal symptom relief. Drugs Aging 2004;21:757-66.
30. Kiser PF, Johnson TJ, Clark JT. State of the art intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 2012;14:62-77.